ARF1 and cancer: Assessment of Arf1 inhibitor efficacy in a preclinical model and evaluation the synergistic anticancer effects of the combination of Arf1 and Ras inhibitors, have immediate potential in reducing cancer morbidity and improving the quality of life of those affected by prostate cancer.